Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi

Authors

  • Eny Nurhikma POLITEKNIK BINA HUSADA KENDARI, PRODI DIII FARMASI
  • Randa Wulaisfan POLITEKNIK BINA HUSADA KENDARI, PRODI DIII FARMASI
  • Musdalipah Musdalipah POLITEKNIK BINA HUSADA KENDARI, PRODI DIII FARMASI

DOI:

https://doi.org/10.33533/jpm.v13i2.1284

Keywords:

Cost effective, ACER, ICER, Hypertension, Candesartan, Amlodipin

Abstract

Today, in various countries, especially in Indonesia, the cost of health services is increasing. Hypertension is a degenerative disease that requires health costs for a long time. Increasing costs due to increasing chronic diseases threaten access and quality of health services, by which it is necessary to find a solution to overcome the problem of health financing. One method used is to analyze the guidelines for hypertension therapy and drug classes in the pharmacoeconomic aspects, namely Cost Effectiveness Analysis. This study aims to analyze the effectiveness of antihypertensive combination therapy in hypertensive patients at Bhayangkara Hospital, Kendari in 2019. The research method is descriptive with cross sectional study design. The analysis conducted is the cost effectiveness analysis (CEA) performed by calculating direct medical costs, the effectiveness of therapy based on blood pressure that reaches the target and calculating the value of ACER (Average Cost Effectiveness Ratio) and ICER (Incremenal Cost Effectiveness Ratio). Data were collected prospectively which fulfilled the inclusion and exclusion criteria. The results showed the therapeutic effectiveness and the value of ACER obtained from 31 hypertensive patients were a combination of Candesartan – Bisoprolol  that was ACER value of 85.71% (2,314), and combination of Candesartan – Amlodipin of 70.58% (2,643). ICER value of 7,832 indicates that the price of drugs is more expensive but more effective therapy.

 

References

Musdalipah, Tee, S. A. (2018). Analisis Efektivitas Biaya Obat Alprazolam dan Diazepam Pada Pasien Depresi di Rumah Sakit Jiwa Provinsi Sulawesi Tenggara. Jurnal IImiah Ibnu Sina, 3(2), 252–260. Retrieved from http://jiis.akfar-isfibjm.ac.id/index.php/JIIS/article/view/175.

Andayani, TM. 2013, Farmakoekonomi prinsip dan metodologi, Bursa ilm, Yogyakarta.

Musdalipah; Setiawan, MA; Santi, E. (2018). Analisis efektivitas biaya antibiotik sefotaxime dan gentamisin penderita pneumonia pada balita di RSUD Kabupaten Bombana Provinsi Sulawesi Tenggara. Jurnal Ilmiah Ibnu Sina, 3(1), 1–11. Retrieved from http://jiis.akfar-isfibjm.ac.id/index.php/JIIS/article/view/104.

Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FR, et al. 2011, Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. The Lancet; 378(9798):1219-1230.

Joel, J. J., Daniel, N., & Shastry, C. S. (2015). Cost Analysis Of Antihypertensive Drugs Prescribed In A Tertiary Care Teaching Hospital. International Journal of Research and Development in Pharmacy and Life Sciences, 4(1), 1371–1374. Retrieved from Available online at http // www.ijrdpl.com.

Szucs, T. D., Waeber, B., & Tomonaga, Y. (2010). Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland : an analysis of the HYVET study from a Swiss perspective. Journal of Human Hypertension, 24(2), 117–123. https://doi.org/10.1038/jhh.2009.47.

Alifiar, I., dan Ida Cahyati, K, 2019, Kajian Farmakoekonomi Penggunaan Obat Antihipertensi pada Pasien Hipertensi yang di Rawat di RSUD Kota Tasikmalaya. Jurnal Pharmascience, 5(2) ; 126 – 133.

Kementrian Kesehatan Republik Indonesia.,2018. Laporan Hasil Riset Kesehatan Dasar (riskesdas) Indonesia tahun 2018. Jakarta. Badan Penelitian dan Pengembangan Kesehatan Kemenkes RI. 2018.

Tambunan, M,E,R, Sopyan,Iyan, 2017, Review Analisis Efektivitas Biaya Terapi Hipertensi dari Berbagai Negara, Farmaka, 14(2) : 182 – 193.

Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, et al. 2015. Cost-effectiveness of hypertension therapy according to 2014 guidelines. New England Journal of Medicine ;372(5):447-55.

Barton, M., Meyer, M.R. 2009. Postmenopausal hypertension mechanism and therapy. Hypertension, 54(11):11-18.

Rustiani, E., Andrajati, R., & Arsyanti, L. (2013). Analisis Penggunaan Obat Antihipertensi di Poliklinik Rawat Jalan Rumah Sakit PMI Bogor: Perbandingan Cost Effectiveness dan Kualitas Hidup Pasien. Jurnal Ilmu Kefarmasian Indonesia, Vol. 12, pp.

Tiwaskar, M., Langote, A., Kashyap, R., & Toppo, A. (2018). Amlodipine in the Era of New Generation Calcium Channel Blockers. Journal of The Association of Physicians of India, 66(March), 59–64.

Fleg JL, Aronow WS, Frishman WH., 2011, Cardiovascular drug therapy in elderly: benefits and challenges. Nature Review Cardiology 8: 13-26.

Baroroh, F., Indonesia, A. S.-P. J. F., & U. (2017). Cost Effectiveness Analysis Therapy Combination of Candesartan-Amlodipine and Candesartan-Diltiazem on Hypertensive Outpatients. Jurnalnasional.Ump.Ac.Id, 14(02), 188–198. Retrieved from http://jurnalnasional.ump.ac.id/index.php/PHARMACY/article/view/1952.

Timur, W.W., Andayani, T.M., Aribawa, R. 2012. Analisis efektifitas biaya kombinasi antihipertensi oral pasien hipertensi rawat jalan di Rumah Sakit Umum Daerah Tugurejo Semarang periode 2007. Jurnal Fakultas Farmasi Universitas Wahid Hasyim Semarang, 4(2):124 - 133.

Tjay, H.T, and Rahardja, K. (2007). Obat-Obat Penting Edisi VI. PT Elex Media Komputindo, Jakarta.

Saseen, J. J., 2008. Essential Hypertension dalam Koda-Kimble, M. A., Young, L. Y., Alldredge, B.K., Corelli, R. L., Guglielmo B. J., KradjanW.a., dan Ninth edition, 34736, Lippincot Williams dan Wilkins, Philadelphia.

Gunawan, 2014, Farmakologi dan Terapi, FK UI, Jakarta

Dipiro, T.J., Talbert, I.R., Yee, C.G., Matzke, R.C ., Weels, G.B dan Posey, M.L., 2005, Pharmacotherapy Handbook Sixth Edition, 415-426, The McGraw-Hill Companies, United States of America

Bekki, H., Yamamoto, K., Sone, M., Homma, T., Nakata, M., Nohara, M., … Yamagishi, S. (2010). Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension. Oxidative Medicine and Cellular Longevity, 3 (5), 342–346. https://doi.org/10.4161/oxim.3.5.13199.

Lorensia, A., dan Doddy, D.Q. 2016. Farmakoekonomi Edisi Kedua. UBAYA, Surabaya

Downloads

Published

2019-12-23

How to Cite

Nurhikma, E., Wulaisfan, R., & Musdalipah, M. (2019). Cost Effectiveness Kombinasi Antihipertensi Candesartan-Bisoprolol dan Candesartan-Amlodipin Pada Pasien Rawat Jalan Penderita Hipertensi. Jurnal Profesi Medika : Jurnal Kedokteran Dan Kesehatan, 13(2). https://doi.org/10.33533/jpm.v13i2.1284

Issue

Vol. 13 No. 2 (2019): Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan

Section

Article

License

Copyright Notice

All articles submitted by the author and published in the Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, are fully copyrighted by the publication of Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher

Note :

The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.

Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).